Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avipendekin pegol - Nektar Therapeutics

Next Previous
X
Search
Drug Profile

Avipendekin pegol - Nektar Therapeutics

Alternative Names: NKTR-255; Polymer-conjugated IL-15 - Nektar Therapeutics

Latest Information Update: 28 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer AbelZeta Pharma; Fred Hutchinson Cancer Research Center; Gilead Sciences; Janssen; M. D. Anderson Cancer Center; Merck KGaA; Nektar Therapeutics; Stanford University
  • Class Antineoplastics; Antivirals; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III B-cell lymphoma; Diffuse large B cell lymphoma
  • Phase II Non-small cell lung cancer; Urogenital cancer
  • Phase I/II Cervical cancer; Colorectal cancer; Squamous cell cancer
  • Preclinical Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Triple negative breast cancer
  • No development reported Multiple myeloma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Viral infections

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, In the elderly, Salvage therapy, Second-line therapy or greater, In adults) in USA (IV, Infusion)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(In the elderly, Monotherapy, Second-line therapy or greater, In adults) in USA (IV, Infusion)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, In the elderly, Salvage therapy, Second-line therapy or greater, In adults) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top